Mandate

Vinge advises Altor, the founders and the other sellers in connection with the divestment of a majority share in Eleda to Bain Capital

Vinge advises Altor Funds (“Altor”), the founders and the other sellers in connection with Bain Capital Private Equity (“Bain Capital”), a leading global private investment firm, acquiring a controlling stake in Eleda from Altor, which will reinvest a minority share. Eleda’s founders, Johan Halvardsson and Peter Condrup, and senior executives in Eleda will also reinvest a substantial share. Through the transaction, Altor, Eleda and Bain Capital establish a partnership for future expansion.

Headquartered in Stockholm and with approximately 3,000 employees, Eleda is a leading Nordic infrastructure development and services provider. The company is the market leader within several segments, many addressing the need of the green transition, including water and sewerage, power distribution, district heating, roads, data centres, railways, and electric vehicle charging stations. Eleda’s decentralised operating model allows its group companies to deliver the highest quality to their customers with the optimal mix of local presence and the resources of a larger organization.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Christina Kokko, Johanna Wiberg, Carl Fredrik Wachtmeister, Ellen Flygt, Philip Moré, Jonatan Stentorp, Jonas Johansson, Nina Gransäter and Johan Gavelin (M&A), Louise Brorsson Salomon and Jolinn Uhlin (Banking and Finance), Martin Johansson and Hedvig Josefson (EU Regulatory), Emy Rydén, Emelie Schoning, Gabriella Balbo, Emma Emsjö, Christoffer Widström and Fanny Askelöf (Transaction Support Coordinators).

Read the client’s press release           

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026